A review of new science, in plain language

Nature Medicine  ·  13 July 2026  ·  From issue 08

An anti-PMEL antibody-drug conjugate with a Gq/11 inhibitor payload in GNAQ/GNA11-mutant melanomas: a phase 1 trial

A new targeted drug shrank tumors in many patients with an aggressive, spreading eye cancer.

Matteo S. Carlino, Ellen Kapiteijn et al.

A new drug shrank tumors in some patients with a rare, hard-to-treat eye cancer that spreads. This cancer often carries specific gene changes that make cells grow out of control. The drug is built to find a marker on cancer cells. It then releases a treatment inside the cell to block that growth signal. In a trial of 66 patients, 13 patients had their tumors shrink a lot. That is about 20 percent. Another 47 patients, or about 71 percent, had some tumor shrinkage. Patients went a median of 7.2 months before their cancer got worse. Serious side effects were uncommon. Only five patients, about 8 percent, had severe treatment-related problems.

Integrity screen: passed (3 checks) Checked 25 August 2026. Read the source

The plain-language reading of this paper is in the full issue, for subscribers.

Read the full issue

Five vetted papers in plain language, free, every two days

Five papers free every issue, about 15 emails a month. No spam. Leave in one click.

Also in issue 08 15 papers
More from Nature Medicine